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The HSPs (hereditary spastic paraplegias) are genetic conditions
in which there is distal degeneration of the longest axons of the
corticospinal tract, resulting in spastic paralysis of the legs.
ThegeneencodingspartinismutatedinTroyersyndrome,anHSP
in which paralysis is accompanied by additional clinical features.
There has been controversy over the subcellular distribution of
spartin. We show here that, at steady state, endogenous spartin
exists in a cytosolic pool that can be recruited to endosomes
and to lipid droplets. Cytosolic endogenous spartin is mono-
ubiquitinated and we demonstrate that it interacts via a PPXY
motif with the ubiquitin E3 ligases AIP4 [atrophin-interacting
protein 4; WWP2 (WW domain-containing E3 ubiquitin protein
ligase 2] and AIP5 (WWP1). Surprisingly, the PPXY motif, AIP4
and AIP5 are not required for spartin’s ubiquitination, and so
we propose that spartin acts as an adaptor for these proteins.
Our results suggest that spartin is involved in diverse cellular
functions, which may be of relevance to the complex phenotype
seen in Troyer syndrome.
Key words: epidermal growth factor receptor (EGFR), hereditary
spastic paraplegia (HSP), microtubule interacting and trafﬁcking
domain, mono-ubiquitination, spartin.
INTRODUCTION
The HSPs (hereditary spastic paraplegias) are genetic conditions
in which the main pathology is degeneration of the distal ends
of the longest axons of the corticospinal tract, the main pathway
that connects the motor cortex of the brain to the spinal cord
[1–4]. Study of the HSPs is therefore important to understand the
molecular mechanisms involved in axonal maintenance and
the dying-back axonopathy seen in these and other more common
neurological conditions.
The HSPs are divided into pure forms, in which spastic
paraplegia occurs in relative isolation, and complex forms, in
which there are other prominent clinical features [1,5]. This
clinical diversity is reﬂected in genetic heterogeneity, and at
present more than 30 genetic loci have been mapped, with
causative mutations in numerous genes identiﬁed [2–4]. One of
these is the SPG20 gene, which encodes spartin. Mutation of this
gene causes Troyer syndrome, an autosomal recessive complex
HSPinwhichspasticparaplegiaisaccompaniedbysevereatrophy
ofthesmallhandmuscles,dysarthria,mentalretardationandmild
skeletal abnormalities, including short stature [6]. The condition
was identiﬁed in the Old Order Amish population, where the
causative mutation is a frameshift that is predicted to cause a
substitution of 29 amino acids before premature truncation of the
protein by 268 residues [6]. This is likely to cause the loss of
the protein [7].
To date, studies aimed at determining the subcellular location
of spartin have largely relied on over-expression systems. Lu
et al. [8] reported that epitope-tagged spartin localized to
mitochondria, whereas Bakowska et al. [9] found that epitope-
taggedspartinwascytosolic,butwassequesteredtoendosomeson
stimulation with EGF (epidermal growth factor) or on expression
of ATPase-defective Vps4 (vacuolar protein sorting 4). ATPase-
defective Vps4 has a dominant-negative effect, trapping proteins
on endosomes that normally have a transient localization there
[10,11].Bakowskaet al.[9]alsoreportedthat endogenousspartin
isrequiredforefﬁcientendosomaldegradationoftheEGFR(EGF
receptor), supporting a role for the protein at endosomes. In
contrast, a very recent report found no recruitment of spastin
to dominant-negative Vps4 endosomes. Instead, epitope-tagged,
over-expressed spartin was found in cultured cells to be cytosolic,
but was recruited to lipid droplets upon induction by oleic acid
treatment [12]. Lipid droplets are cytoplasmic structures, bound
by a monolayer of polar lipids, which store neutral lipids in
their core. They are found in nearly all cell types and play
active roles in lipid homoeostasis and a number of other cellular
functions [13,14]. In summary, existing localization studies have
been of uncertain relevance to endogenous spartin and have given
contradictory results.
Spartin is multiply mono-ubiquitinated [9]. Using over-
expression systems in a study published during the preparation of
this manuscript, Eastman et al. [12] found that spartin interacts
with the HECT (homologous with the E6AP C-terminus) family
ubiquitin E3 ligase AIP5 [atrophin-interacting protein 5, WWP1
(WWdomain-containingE3ubiquitinproteinligase1)],although
the relevance of this interaction to the endogenous proteins was
not demonstrated. HECT ubiquitin ligases contain an N-terminal
membrane-binding C2 domain, WW domains that interact with
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PPXY motifs in binding partners and a C-terminal HECT
domain that has ubiquitin binding and ligation properties [15].
The interaction was mediated by binding between a spartin
PPXY motif and WW domains in the E3 ligase, and over-
expressionexperimentssuggestedthatAIP5mightberesponsible
for ubiquitination of spartin [12].
In the present study, we identiﬁed the subcellular locations of
endogenous spartin, demonstrating that it is present in a cytosolic
pool that can be sequestered to endosomes and to lipid droplets.
We also identiﬁed interactions at the endogenous protein level
between spartin and the E3 ubiquitin ligases AIP4 and AIP5.
Surprisingly, we show that spartin’s PPXY motif, AIP4 and AIP5
are not required for spartin’s ubiquitination. Instead, we suggest
that spartin has a more complex relationship with these ubiquitin
ligases, perhaps functioning as an adaptor for them.
EXPERIMENTAL
Antibodies and markers
Mouse monoclonal anti-α-tubulin (T-9026) and anti-FLAG (A-
9594) and rabbit polyclonal anti-actin (A-2066) were from
Sigma–Aldrich. Goat polyclonal anti-AIP4 (Sc-11890) and
mousemonoclonalanti-LAMP1(lysosome-associatedmembrane
protein 1; clone H4A3) were from Santa Cruz Biotechnology.
Mouse monoclonal anti-AIP5 (H00011059-M01) was from
Abnova. Mouse monoclonal anti-EEA1 (early endosome
antigen 1; 610457) and anti-GM130 (610823) were from
BD Transduction Laboratories. Mouse monoclonal anti-EGFR
(Ab-5) and rabbit polyclonal anti-calreticulin (Ab-4) were
from Calbiochem. Mouse monoclonal antibodies to polyubi-
quitinated protein (FK1) and poly- and mono-ubiquitinated
proteins (FK2) were from Biomol International. Mouse
monoclonal anti-HA (haemagglutinin; code number HA.11) was
from Covance. Sheep polyclonal anti-TGN46 (AHP500G)
was from AbD Serotec. Mouse monoclonal anti-KDEL (SPA-
827) was from Stressgen. Mouse monoclonal anti-Myc (4A6)
was from Upstate Biotechnology. Rabbit polyclonal anti-GFP
(green ﬂuorescent protein; catalogue number 6556-25) was from
AbCam. Mouse monoclonal anti-clathrin (X22) was a gift
from Professor Margaret S. Robinson (Department of Clinical
Biochemistry, University of Cambridge, Cambridge, U.K.).
Rabbit polyclonal anti-spartin was raised against full-length
GST (glutathione transferase)–spartin (Harlan SeraLabs). Rabbit
polyclonal anti-M6PR was raised as previously described [16].
Peroxidase-conjugated secondary antibodies for Western blotting
were obtained from Sigma–Aldrich. MitoTracker and Alexa
Fluor®-labelled secondary antibodies for immunoﬂuorescence
were from Invitrogen Molecular Probes.
Constructs
The full-length cDNA for spartin was ampliﬁed by PCR from
the IMAGE clone 4738886. To make GST–spartin, the PCR
primers used in the reaction contained restriction enzyme
sites compatible with cloning into the pGEX-4T3 expression
vector (GE Healthcare), which coded for a 5
  in-frame GST
tag. The PCR product was ligated into the expression vector
using T4 DNA ligase (New England Biolabs). The sequence
of the inserted cDNA and insertion sites was veriﬁed by
sequencing (Geneservice). For the Myc–spartin and Myc–
spartinAAAA (mutation of spartin’s PPXY motif to AAAA)
constructs, Gateway-compatible primers were used to amplify
the spartin cDNA, and the PCR product was then ligated into a
pcDNA3-NG-Myc Gateway-compatible vector, using previously
described methods [17]. Site-directed mutagenesis of this vector
was carried out using the Phusion Site-Directed Mutagenesis
kit (Finnzymes). The Myc–Nedd4.2 (neural-precursor-cell-
expressed developmentally down-regulated 4.2) constructs were
a gift from Dr Adriano Marchese (Department of Pharmacology
and Experimental Therapeutics, Loyola University, Chicago,
IL, U.S.A.), whereas the AIP4 constructs were a gift from
Professor Paul Lehner (Department of Medicine, School of
Clinical Medicine, University of Cambridge, Cambridge, U.K.).
Cell culture, transient transfection of DNA and
immunoﬂuorescence microscopy
HeLa (human cervical carcinoma), NSC34 (a hybrid murine
motor neuron/neuroblastoma cell line) and PC12 (a rat
neuroendocrine cell line) cells were maintained in DMEM
(Dulbecco’s modiﬁed Eagle’s medium; Sigma–Aldrich) contain-
ing 10% FBS (fetal bovine serum; Sigma–Aldrich), 100 units/ml
penicillin, 100 μg/ml streptomycin (Sigma–Aldrich) and 2 mM
L-glutamine (Sigma–Aldrich). PC12 medium also contained
10% horse serum.
Transient transfections of plasmid DNA constructs were
carried out using Effectene® transfection reagent (Qiagen) as
previously described [18,19]. Following transfection, coverslips
to be processed for immunoﬂuorescence were washed twice in
PBS (Sigma–Aldrich). In cases where cytosol extraction was
undertaken, cells were washed twice with ice-cold 1× PBS and
once with cytosol extraction buffer [25 mM Hepes/KOH, 25 mM
KCl, 2.5 mM magnesium acetate, 5 mM EGTA (sodium free) and
150 mM potassium glutamate] before being washed with cytosol
extraction buffer supplemented with 0.05% saponin for 30 s.
In most cases, cells were ﬁxed with 3.8% (w/v) formaldehyde
in 1× PBS at room temperature (22◦C) for 20 min, and
then permeabilized with 0.1% Triton X-100 (Sigma-Aldrich)
or 0.05% saponin (Sigma; for LAMP1 antibody) at room
temperature for 4 min. Cells to be immunostained with anti-
EGFR or X-22 were ﬁxed and permeabilized in methanol at
−20◦C for 5 min. Further processing was then carried out as
previously described in [18]. Coverslips were mounted in anti-
Fade Gold medium (Invitrogen Molecular Probes) on a glass
slide. Stained samples were viewed under a Zeiss 510 Meta
confocal microscope. Images were recorded using LSM Image
Analyzer software and data were subsequently processed using
Adobe Photoshop and Illustrator programmes.
Protein depletion by siRNA (small interfering RNA) knockdown
Duplex siRNA oligonucleotides targeting human spartin
(GGCAAGGAUUGGAAUGUGCAGCUAA and CAAAUACG-
GAUAUAAUGCAGGAGAA, siRNA1 and siRNA2 respectively,
[9]) and AIP4 (GGUGACAAAGAGCCAACAGAGTT) were
obtained from Invitrogen. AIP5 On-Target smartpool siRNA,
used in a pool containing 4 oligonucleotides (GGUCUGAUA-
CUAGUAAUAA, GAACGCGGCUUUAGGUGGA, GAAAA-
GCAACGAUAGAUUU and CCAGAUGGAUUGAAGAGUU,
catalogue numbers J-004251-07 to -10) and non-targeting control
siRNA (#1, catalogue number D-001210-01) were obtained from
Dharmacon.
For siRNA transfection, a ‘double hit’ oligonucleotide
transfection protocol, using Oligofectamine transfection reagent
(Invitrogen), was employed as previously described [19]. Spartin
oligonucleotides were used separately at 10 nM concentration,
or in combination at a total concentration of 10 nM. The AIP4
oligonucleotide was used at 50 nM and the AIP5 smartpool at a
total concentration of 200 nM. Protein depletion was conﬁrmed
in each experiment by immunoblotting.
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Figure 1 A novel anti-spartin antibody conﬁrms that spartin shows multiple mono-ubiquitination
(A) Western blot (WB) of HeLa, NSC34 and PC12 lysates using α-spartin ﬁnal bleed (left panel) or pre-immune serum (PI, right panel). (B) HeLa cells transfected with control non-targeting
siRNA show a strong ∼80kDa band on immunoblotting with α-spartin, whereas in cells transfected with each of two siRNA oligonucleotides directed against spartin, or with a pool of the
two spartin siRNAs, this band is absent. Actin immunoblotting is shown to verify equal loading. (C) Spartin was immunoprecipitated (IP) from Hela cells by α-spartin, but not by pre-immune
serum. (D) Spartin was immunoprecipitated from HeLa cells by α-spartin. Subsequent immunoblotting with FK2 (which recognizes mono- and poly-ubiquitin) detected bands corresponding to
the expected size of ubiquitinated forms of spartin, whereas immunoblotting with FK1 (which recognizes only poly-ubiquitin) detected no signal. (E) HeLa cells were transfected with HA-tagged
ubiquitin, then immunoprecipitated with α-spartin or with pre-immune serum. Immunoblotting with anti-HA antibody detected bands corresponding to the size of ubiquitinated spartin in the sample
immunoprecipitated with α-spartin. (F) Underimmunoﬂuorescenceconfocalmicroscopy,mock-transfected HeLacells show astrong cytosolic signal when labelled withα-spartin. However,in cells
transfected with an siRNA oligonucleotide directed against spartin, the signal was greatly diminished. Images were obtained using identical confocal microscope settings. Scale bars=10μm.
Co-immunoprecipitation
Cells were harvested by scraping them into ice-cold lysis buffer
containing 1% Triton X-100, centrifuged at 10000 g for 5 min
at 4◦C to remove insoluble material, and then processed as
previously described in [18].
Lipid droplet induction and labelling
To induce lipid droplet formation, HeLa cells were cultured in
DMEM supplemented with 200 μM oleic acid (Sigma–Aldrich)
in0.3%BSAfor24 h,aspreviouslydescribedin[12].Lipiddrop-
lets were visualized by incubating the cells in PBS with 10 μg/ml
BODIPY 493/503 (Invitrogen) for 15 min before ﬁxation.
RESULTS
Spartin is mono-ubiquitinated in human and rat cell lines
To characterize better endogenous spartin, we raised a polyclonal
antibody (termed α-spartin) against a GST-tagged full-length
spartin fusion protein. We ﬁrst veriﬁed this antibody for use in
Western blotting and immunoprecipitation. In Western blotting
with HeLa, NSC34 and PC12 cells, the antibody detected a
main band of approx. 80 kDa, consistent with the size predicted
for endogenous spartin (Figure 1A). In NSC34 cells, a band of
approx. 70 kDa was also seen, which may represent a lower-
molecular-mass isoform of the protein. In HeLa cells, the
80 kDa band was greatly diminished after depletion of spartin
by siRNA transfection, conﬁrming the speciﬁcity of the antibody
(Figure1B).Astrong80 kDabandwasalsodetectedonimmuno-
blotting with α-spartin after the antibody was used in
immunoprecipitation experiments (Figure 1C), and mass spectro-
scopic analysis conﬁrmed that spartin protein was present in the
immunoprecipitate (results not shown).
It has been reported that spartin is multiply mono-ubiquitinated
[9], and in our immunoblotting experiments we saw fainter bands
above the main 80 kDa spartin band in HeLa, NSC34 and PC12
cells (Figure 1A). After immunoprecipitation of spartin from
HeLa cells, blotting with antibodies recognizing either mono-
andpoly-ubiquitin(FK2)orpolyubiquitinalone(FK1)conﬁrmed
c   The Authors Journal compilation c   2009 Biochemical Society © 2009 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.34 T. L. Edwards and others
that these larger bands represented mono-ubiquitinated forms
of spartin (Figure 1D). Similar results were found in NSC34
cells (results not shown). In addition, in HeLa cells transiently
transfected with HA–ubiquitin and immunoprecipitated with
α-spartin, bands corresponding to the size of ubiquitinated
spartin were detected with anti-HA antibody on immunoblotting
(Figure 1E). We therefore conclude that spartin is multiply mono-
ubiquitinated.
Endogenous spartin can be recruited to endosomes
To resolve the conﬂicting descriptions of the subcellular
location of spartin [8,9,12], we determined the subcellular dis-
tribution of endogenous spartin using our α-spartin antibody.
In immunoﬂuorescence experiments, endogenous spartin had
a widespread diffuse cytoplasmic distribution with typically
minimal nuclear staining (Figure 1F). The intensity of the
signal was signiﬁcantly reduced on depletion of spartin by
siRNA knockdown, conﬁrming the speciﬁcity of the antibody
(Figure 1F).
We ﬁrst co-stained HeLa cells with α-spartin and a variety
of organelle markers. There was no, or very limited, co-
localization with markers for endosomes, lysosomes, the Golgi
apparatus, clathrin-coated vesicles, the endoplasmic reticulum or
microtubules(SupplementaryFigureS1athttp://www.BiochemJ.
org/bj/423/bj4230031add.htm). We next examined whether
endogenous spartin could be trapped on Vps4-EQ-positive
endosomes, an issue that has been controversial in experiments
with epitope-tagged spartin [9,12]. Endogenous spartin was
strongly recruited to these (Figure 2A). This suggests that
endogenous spartin has a transient association with endosomes,
and its removal from them requires Vps4.
Upon stimulation of cells with physiological doses of EGF,
EGF binds to EGFRs, whereupon the EGF/EGFR complex is
internalized via clathrin-mediated endocytosis,thentrafﬁcked via
early and late endosomes to the lysosomal compartment, where it
is degraded [20]. On EGF stimulation, over-expressed epitope-
tagged spartin is recruited initially to the plasma membrane
and then associates with EGF-positive structures for up to
30 min chase time, after which no co-localization is found
with ﬂuorescently labelled EGF [9]. We examined whether
endogenous spartin behaved in the same way. We incubated
cells that had been serum starved for at least 3 h with EGF
(5 ng/ml) on ice for 1 h. We then warmed the cells to 37◦Ct o
trigger a pulse of receptor internalization. As expected, we saw
EGFR internalization from the plasma membrane to cytoplasmic
vesicular stuctures (Figures 2B and 2C). In contrast with the
results obtained previously with epitope-tagged spartin, we found
no strong recruitment of endogenous spartin to the plasma
membrane at early chase times [0 min (results not shown) and
1 min; Figure 2B], and at these time points there was no obvious
co-localization between spartin and EGFR. However, we began
to see co-localization between spartin and EGFR at 5 min chase
time (results not shown), and this partial co-localization between
spartin and EGFR was also present at 30 min (Figure 2C) and
60 min (results not shown).
Spartin has been reported necessary for efﬁcient degradation
of EGFR [9]. In HeLa cells stimulated with 100 ng/ml of EGF,
we found that depletion of spartin caused a 26% reduction in
EGFR degradation after stimulation with EGF for 1 h, compared
with mock-transfected cells (Figure 2D; P=0.004; one-tailed
paired t test), consistent with the previous report. Together with
the immunoﬂuorescence data, this indicates that endogenous
cytosolic spartin can be recruited to, and function at, endosomes.
Endogenous spartin is recruited to lipid droplets
Very recently, epitope-tagged spartin has been reported to be
recruited to lipid droplets induced by oleic acid treatment in
culturedcells[12].Weexaminedtherelevanceofthisobservation
totheendogenousprotein.InHeLacells,weinducedlipiddroplet
formation by adding 200 μM oleic acid to the culture medium for
12–24 h. The spartin signal often surrounded the resulting lipid
droplets, and where lipid droplets were clustered, this resulted
in a ‘honeycomb’ appearance that was reminiscent of that found
with over-expressed spartin (Figures 3A and 3B) [12]. In some
cases, spartin decorated the lipid droplet in patches, perhaps
suggesting that it is present on speciﬁc lipid droplet surface
domains (Figures 3A and 3B).
We also examined whether there was any co-localization
between spartin and mitochondrial markers. To facilitate this
examination, we removed cytosolic diffuse spartin staining by
pre-ﬁxation treatment with a saponin-based cytosolic extraction
buffer. In HeLa cells, removal of cytosolic spartin revealed
numerous punctate and tubular structures, and the labelling
intensity of these was diminished by spartin siRNA knock-
down (Supplementary Figure S2 at http://www.BiochemJ.org/
bj/423/bj4230031add.htm). There was co-localization between
the mitochondrial marker MitoTracker and the majority of the
spartin-positive puncta (Supplementary Figure S2). Although
one group has reported localization of epitope-tagged spartin
to mitochondria, subsequent studies have not veriﬁed this result
using a variety of epitope tags [9,12] and in our hands neither
Myc- nor GFP-tagged spartin co-localized with mitochondria
(results not shown). Lipid droplets have been reported in close
association with mitochondria [21], but we found only a minimal
overlap between the spartin associated with lipid droplets and
mitochondria (Figure 3B).
Spartin interacts with the HECT-family ubiquitin ligases AIP4 and
AIP5 via a PPXY motif
Severalproteinsinvolvedinendocyticprocessesareubiquitinated
by members of the Hect/Nedd4 family of ubiquitin E3 ligases.
A previous proteomics study examining the interaction proﬁle
of WW domains suggested an interaction between the WW-
domain of the Hect/Nedd4 ubiquitin ligase family member AIP4
and spartin, raising the possibility that AIP4 has ubiquitin ligase
activitytowardsspartin[22].Inaddition,astudypublishedduring
the preparation of the present manuscript used over-expression
systems to show that AIP5 also interacts with spartin [12]. We
therefore investigated the relevance of these potential interactions
to the endogenous protein.
In HeLa cells, endogenous spartin co-immunoprecipitated
with endogenous AIP4 and AIP5 (Figures 4A and 4B). Using
immunoﬂuorescence microscopy, spartin and AIP4 showed
partial co-localization in small puncta (Figure 4C). These experi-
ments strongly support the presence of a physiologically relevant
interaction between spartin, AIP4 and AIP5. In the case of AIP4,
this interaction did not require AIP4’s ubiquitin ligase activity,
since both wild-type FLAG-tagged AIP4 and ligase-defective
AIP4 co-immunoprecipitated equally well with endogenous
spartin(Figure4D).WithintheHect/Nedd4family,theinteraction
of AIP4 and AIP5 with spartin showed some speciﬁcity, since we
found no interaction between spartin and another member of the
Hect/Nedd4 family, Nedd4.2 (Figure 4E).
We noted that spartin contains a PPXY motif (residues 171–
174; Figure 5F). In many cases, binding of Nedd4 family E3
ligases to target proteins is mediated by interactions between
WW domains in the E3 ligase and PPXY motifs in the target
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Figure 2 Endogenous spartin can be recruited to endosomes
(A) Endogenous spartin was recruited onto Vps4-EQ-positive puncta in HeLa cells transfected with Vps4-EQ–GFP. Arrows indicate individual puncta that show co-localization. The inset shows a
magniﬁed image of the boxed area. (B–C) HeLa cells were incubated with EGF (5ng/ml in medium) on ice for 1 h, then placed into warm serum-free medium to initiate a synchronized pulse of
EGFRendocytosis,andprocessedforimmunoﬂuorescenceattheindicatedtimes.At1 minchase,EGFRwaspredominantlyontheplasmamembraneandnoco-localizationwithspartinwaspresent.
At 30min chase, spartin showed co-localization with the endocytosed EGFR. Arrows indicate individual puncta that show co-localization. The insets show magniﬁed images of the boxed areas. In
(A–C) and in subsequent micrograph panels, right-hand panels show the merged images; the colour of each marker in the merged image is shown by the colour of its lettering in the non-merged
panels. Scale bars=10μm. (D) Graph showing EGFR immunoblot density in mock-transfected or spartin-depleted cells stimulated with 100ng/ml of EGF for the times indicated (n=4, one-tailed
paired t test). The corresponding immunoblots show a representative experiment.
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Figure 3 Endogenous spartin can be recruited to lipid droplets
(A) HeLa cells were treated with oleic acid (200μM for 24h) and lipid droplets were labelled by incubation with BODIPY 493/503. Cells were then ﬁxed and labelled for spartin. A spartin signal
often surrounded the lipid droplets and, where lipid droplets clustered, a honeycomb appearance was seen (see boxed area; inset shows a magniﬁed image of the boxed area). (B) A cell in which
lipid droplet formation was induced in the same way as in (A). The cell was labelled with the mitochondrial marker MitoTracker, as well as with α-spartin and BODIPY 493/503. The spartin signal
surrounds many of the lipid droplets; an example is indicated by the arrowheads. The spartin label around the lipid droplets shows minimal co-localization with MitoTracker. Scale bars=10μm.
protein [15]. On mutation of the PPXY to AAAA, spartinAAAA,
the association between epitope-tagged spartin and AIP4 or AIP5
was lost, indicating that spartin’s PPXY domain is necessary for
these interactions (Figures 4G and 4H).
The PPXY motif, AIP4 and AIP5 are not required for ubiquitination
of spartin
We next examined whether AIP4 or AIP5 are required for mono-
ubiquitination of spartin. We began by investigating whether
mutation of spartin’s PPXY motif (which is required for
binding to AIP4 and AIP5) affected spartin’s ubiquitination. We
immunoprecipitedwild-typeMyc–spartinorMyc–spartinAAAA,
then immunoblotted with the anti-ubiquitin FK2 antibody.
Mutation of the PPXY motif made no difference to ubiquitination
ofspartin(Figure5A),suggestingthattheinteractionofthismotif
with WW domains of HECT E3 ligases is not required for this.
We determined whether expression of wild-type or
ligase-defective AIP4 affected spartin’s ubiquitination. After
transfection of HeLa cells with FLAG-tagged wild-type or
catalytically inactive AIP4, we blotted against spartin and
assessed whether the higher-molecular-mass ubiquitinated band
was altered. There was no obvious difference in the amount of
ubiquitinated spartin, or indeed total spartin, in cells expressing
wild-type AIP4, catalytically inactive AIP4 or untransfected cells
(Figure 5B). We also examined the effects of AIP4 and/or AIP5
depletion by siRNA knock-down on the higher-molecular-mass
ubiquitinated spartin band. We saw no effect on the amount
of ubiquitinated spartin, or total spartin, in cells depleted of
AIP4, AIP5, or both, compared with control cells, suggesting that
neither AIP4 nor AIP5 are required for ubiquitination of spartin
(Figure 5C).
DISCUSSION
There has been considerable controversy over the subcellular
localization of spartin. Most studies to date have relied on over-
expression systems that have given conﬂicting results. A single
study reporting the localization of the endogenous protein used
an antibody whose speciﬁcity was not verifed by knockdown
experiments and gave discrepant results to all of the over-
expression studies [23]. To resolve this controversy, we used
a novel spartin antibody in immunoﬂuorescence experiments.
Importantly,thespeciﬁcityofthisantibodywasveriﬁedbysiRNA
knock-down.
Twoofthepreviouslocalizationstudiessuggestedthatepitope-
tagged spartin has a predominantly diffuse cytosolic localization
atsteadystate[9,12],andourresultsontheendogenousproteinare
in agreement with this; much of the spartin immunoﬂuorescence
s i g n a lc o u l db er e m o v e db yp r e ﬁ x a t i o nt r e a t m e n tw i t ha
saponin-based cytosol extraction buffer. However, there was
disagreement between the prior studies on whether spartin can
be recruited to endosomes. Bakowska et al. [9] reported that
epitope-tagged spartin was recruited to dominant-negative Vps4-
induced endosomes and could be recruited to endosomes on
EGF stimulation. In contrast, Eastman et al. [12] reported no
recruitment of epitope-tagged spartin to Vps4 dominant-negative
endosomes. We clearly found that endogenous spartin can be
recruited to endosomes under some circumstances; spartin was
trapped on dominant-negative Vps4-induced endosomes, and
EGF stimulation resulted in co-localization between spartin
and endosomal structures. In keeping with this observation, we
(in the present study) and others have shown that spartin is
required for efﬁcient EGFR degradation [9]. Our results from
the present study therefore support a functional role for spartin at
endosomes. Thus spartin is a member of an ‘endosomal’ group of
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Figure 4 Spartin interacts with AIP4 and AIP5
(A) Western blotting (WB) against endogenous AIP4 detects an AIP4-sized band after immunoprecipitation (IP) of HeLa cell lysate with α-spartin, but not with pre-immune (PI) serum.
(B) Immunoblotting against endogenous AIP5 detects an AIP5-sized band after immunoprecipitation of HeLa cell lysate with α-spartin, but not with pre-immune serum. (C) Endogenous
spartin partially co-localizes with endogenous AIP4, in small puncta. Arrows indicate puncta showing co-localization. The inset shows a magniﬁed image of the boxed area. Scale bar=10μm.
(D) Endogenous spartin was immunoprecipitated from HeLa cells transfected with FLAG-tagged wild-type AIP4 or catalytically inactive AIP4 (C803A). Immunoblotting with anti-FLAG demonstrated
that wild-type and catalytically inactive AIP4 were co-immunoprecipitated with spartin. Neither spartin nor the AIP4 proteins were immunoprecipitated by pre-immune serum. UT, untransfected cells.
(E) Endogenous spartin was immunoprecipitated from HeLa cells transfected with wild-type (wt) or catalytically inactive (C962S; mut.) Myc-tagged Nedd4.2. Immunoblotting with anti-Myc showed
that the Nedd4.2 proteins had not been co-immunoprecipitated with spartin. (F) Sequence of the ﬁrst 210 amino acids of spartin. The MIT (microtubule-interacting and transport) domain is shown
in bold, the PPXY motif is boxed. (G) HeLa cells were transfected with FLAG-AIP4 and either wild-type Myc-tagged spartin (WT) or Myc-tagged spartin in which the PPXY motif had been mutated
to AAAA. After immunoprecipitation with anti-Myc, FLAG-AIP4 co-immunoprecipitated with WT Myc–spartin, but not Myc–spartinAAAA. (H) HeLa cells were transfected with wild-type Myc–tagged
spartin(leftpanels)orMyc–spartinAAAA(rightpanels).Afterimmunoprecipitationwithanti-Myc,endogenousAIP5co-immunoprecipitedwithwild-typeMyc-spartin,butnotwithMyc–spartinAAAA.
An additional short exposure is shown so that immunoblotting results for the input lanes can be properly visualized.
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Figure 5 PPXY, AIP4 and AIP5 are not required for spartin’s ubiquitination
(A) Wild-type (WT) Myc–spartin and Myc–spartinAAAA were immunoprecipitated (IP) from HeLa cells using anti-Myc antibody. Blotting with FK2 (which recognizes poly- and mono-ubiquitin)
revealed similar levels of ubiquitination of both forms of spartin. No bands were seen in samples immunoprecipitated with a spurious antibody directed against actin (results not shown). (B)
Neither ubiquitination of spartin (as indicated by the density of the higher-molecular-mass ubiquitinated band) nor the concentration of spartin differed between untransfected HeLa cells, HeLa
cells transfected with wild-type FLAG-tagged AIP4 (WT AIP4), or with catalytically inactive FLAG–AIP4 (C830A). (C) AIP4 depletion, AIP5 depletion or depletion of both proteins did not affect the
concentration of spartin or the strength of the upper ubiquitinated band seen on spartin immunoblotting. In (B)a n d( C), actin immunoblotting is shown to verify equal loading.
HSP proteins that includes spastin [19], NIPA1 (Non imprinted
in Prader-Willi/Angelman syndrome 1 [24,24a]), maspardin [25]
and spastizin [26]. This suggests that endosomal abnormality,
perhaps resulting in dysregulation of one or more receptor-
mediated signalling pathways important for axonal function,
could be an important cause of HSP.
It has been suggested recently that exogenously expressed
spartin localizes to lipid droplets and that spartin is involved in
lipid droplet turnover [12]. Our results are in agreement with
these observations and extend them by showing that endogenous
spartinispresentonlipiddroplets.Todate,abnormallipiddroplet
biology has not been implicated in the causation of other genetic
subtypes of HSP, and further work will be required to assess the
importance of this function to the axonal degeneration or other
clinical features seen in Troyer syndrome.
Lu et al. [8] reported that N-terminal CFP (cyan ﬂuorescent
protein)-tagged spartin co-localized with mitochondrial markers,
although we (in the present study) and others [12] have found
no localization of exogenous spartin, tagged with either single
epitopes or with ﬂuorescent protein domains, to mitochondria. In
addition, spartin contains no recognized mitochondrial targeting
signal motif. However, after removal of cytosolic spartin,
we did ﬁnd some co-localization of endogenous spartin with
mitochondria, and this signal appeared to diminish, but not
disappear, on spartin knock-down. Thus additional experiments
beyondthescopeofthepresentstudywillberequiredtoprovidea
deﬁnitive answer as to whether spartin is present in mitochondria.
Spartin is mono-ubiquitinated [9]. Mono-ubiquitination is
important at several levels during the endocytosis and
degradationofplasma-membranereceptors.Mono-ubiquitination
of receptors, e.g. EGFR, can act as a signal to promote
their endocytosis and sorting to the late endosomal/lysosomal
degradativecompartment[20,27].Inaddition,muchofthecellular
machinery involved in this endocytic sorting process is itself
mono-ubiquitinated, and some members of this machinery, e.g.
eps15, epsin and Hrs, show coupled mono-ubiquitination, a
phenomenon in which proteins that contain a ubiquitin-binding
domain are themselves mono-ubiquitinated [28,29]. To try to
understand better the basis of spartin’s mono-ubiquitination,
we examined a putative interaction between AIP4 and spartin,
suggested by a proteomics study [22]. We found strong evidence
of a physiologically relevant interaction between endogenous
AIP4 and spartin. We also found an interaction between
endogenous spartin and AIP5, an E3 ligase closely related to
AIP4. In both cases, this interaction was mediated by a PPXY
motif in spartin. These results extend the ﬁndings of a paper
publishedduringthepreparationofthepresentmanuscript,which
used over-expression systems to show that spartin interacts with
AIP5 via a PPXY–WW domain interaction, without proving the
relevance of this interaction to the endogenous situation [12].
Using over-expression systems, Eastman et al. [12] suggested
that AIP5 has ubiquitin ligase activity towards spartin. However,
our results from the present study indicate that ubiquitination of
spartin is unaffected by mutation of the PPXY motif, which has
been shown by our experiments and by Eastman et al. [12] to
be required for binding to WW-domain containing E3 ligases.
In addition, over-expression of wild-type or dominant-negative
AIP4,orsiRNA-mediateddepletionofAIP4,AIP5orboth,allhad
no effect on spartin’s concentration or on its ubiquitination. Our
resultsthereforesuggestthatneitherAIP4,AIP5,northecapacity
to interact with WW-domain containing E3 ligases via its PPXY
motif, are necessary for ubiquitination of spartin. It is possible
that weak or very transient binding to HECT E3 ligases, below
the level detectable by our co-immunoprecipitation experiments,
remains after mutation of the classical PPXY, and that, in the
absence of AIP4 and AIP5, other HECT family E3 ligases may
be sufﬁcient to ubiquitinate spartin. Alternatively, the function of
Nedd4-type E3 ligases may be affected by a number of accessory
and adaptor proteins that are not necessarily ubiquitinated by
the ligase, but which can determine localization of the ligase to
a speciﬁc subcellular compartment, mediate or stabilize the in-
teraction between the ligase and target proteins, or modify the
ligase function of the protein [30]. For example, in the case of
AIP4,anumberofadaptorproteinshavebeenidentiﬁed,including
Numb and certain Smad proteins, which interact with AIP4 via
PPXY–WWdomaininteractions[30].Wethereforespeculatethat
spartin may be an adaptor protein that regulates the function of
AIP4/AIP5 and perhaps other HECT family E3 ligases.
Insummary,takentogetherwiththeresultsofotherstudies,our
work from the present study suggests that spartin has a number
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of roles, including functioning at endosomes and in lipid droplet
formation. This complexity of function could be reﬂected in the
complex phenotype seen with Troyer syndrome, with different
aspects of the condition being caused by abnormality of spartin’s
differentfunctions.Afullexplanationforthediseasewillrequirea
thorough understanding of spartin’s functions at all of these sites
and an exploration of the relevance of each function to axonal
biology.
AUTHOR CONTRIBUTION
Thomas Edwards designed the research, performed the research and analysed data.
Virginia Clowes performed the research and analysed data. Hilda Tsang and James
Connell performed the research. Christopher Sanderson designed the research. J. Paul
Luzio designed the research and critically read the manuscript. Evan Reid designed the
research, performed the research, analysed data and wrote the manuscript.
ACKNOWLEDGEMENTS
We thank Adriano Marchese for providing Nedd4 constructs and Paul Lehner for AIP4
constructs. We thank Margaret S. Robinson and Matthew Seaman for the gift of antibody
reagents. We thank Meredith Ross and Andrew James for helpful discussions. We thank
MichaelMurphyforhelpfuldiscussionsandforhiscriticalreadingofthemanuscriptprior
to submission.
FUNDING
We thank the Tom Wahlig Stiftung and the UK Familial Spastic Paraplegia Family Group
forﬁnancialsupport.E.R.isaWellcomeTrust SeniorResearch FellowinClinicalScience
[grant number 082381], T.L.E. is supported by a UK Government ORS Award and by the
CambridgeCommonwealthTrust,H.T.issupportedbyaCroucherFoundationScholarship
and V.C. is an MRC Research Training Fellow [grant number G0800435]. T.L.E. and
V.C.areSacklerFellows.ThisworkwasalsosupportedbyaMRCprogrammegrant[grant
number G9310915 (to J.P.L.)] and a Wellcome Trust Strategic Award [grant number
079895 (to Cambridge Institute for Medical Research)].
REFERENCES
1 Harding, A. E. (1993) Hereditary spastic paraplegias. Semin. Neurol. 13,
333–336
2 Reid, E. (2003) Science in motion: common molecular pathological themes emerge in
the hereditary spastic paraplegias. J. Med. Genet. 40, 81–86
3 Fink, J. K. (2006) Hereditary spastic paraplegia. Curr. Neurol. Neurosci. Rep. 6,
65–76
4 Soderblom, C. and Blackstone, C. (2006) Trafﬁc accidents: molecular genetic insights
into the pathogenesis of the hereditary spastic paraplegias. Pharmacol. Ther. 109,
42–56
5 Harding, A. E. (1983) Classiﬁcation of the hereditary ataxias and paraplegias. Lancet 1,
1151–1155
6 Patel, H., Cross, H., Proukakis, C., Hershberger, R., Bork, P., Ciccarelli, F. D., Patton,
M. A., McKusick, V. A. and Crosby, A. H. (2002) SPG20 is mutated in Troyer syndrome,
an hereditary spastic paraplegia. Nat. Genet. 31, 347–348
7 Bakowska, J. C., Wang, H., Xin, B., Sumner, C. J. and Blackstone, C. (2008) Lack of
spartin protein in Troyer syndrome: a loss-of-function disease mechanism? Arch.
Neurol. 65, 520–524
8 Lu, J., Rashid, F. and Byrne, P. C. (2006) The hereditary spastic paraplegia protein
spartin localises to mitochondria. J. Neurochem. 98, 1908–1919
9 Bakowska, J. C., Jupille, H., Fatheddin, P., Puertollano, R. and Blackstone, C. (2007)
Troyer syndrome protein spartin is mono-ubiquitinated and functions in EGF receptor
trafﬁcking. Mol. Biol. Cell 18, 1683–1692
10 Stuchell-Brereton, M. D., Skalicky, J. J., Kieffer, C., Karren, M. A., Ghaffarian, S. and
Sundquist, W. I. (2007) ESCRT-III recognition by VPS4 ATPases. Nature 449, 740–744
11 Obita, T., Saksena, S., Ghazi-Tabatabai, S., Gill, D. J., Perisic, O., Emr, S. D. and
Williams, R. L. (2007) Structural basis for selective recognition of ESCRT-III by the AAA
ATPase Vps4. Nature 449, 735–739
12 Eastman, S. W., Yassaee, M. and Bieniasz, P. D. (2009) A role for ubiquitin ligases and
Spartin/SPG20 in lipid droplet turnover. J. Cell Biol. 184, 881–894
13 Thiele, C. and Spandl, J. (2008) Cell biology of lipid droplets. Curr. Opin. Cell Biol. 20,
378–385
14 Fujimoto, T., Ohsaki, Y., Cheng, J., Suzuki, M. and Shinohara, Y. (2008) Lipid droplets: a
classic organelle with new outﬁts. Histochem. Cell Biol. 130, 263–279
15 Ingham, R. J., Gish, G. and Pawson, T. (2004) The Nedd4 family of E3 ubiquitin ligases:
functional diversity within a common modular architecture. Oncogene 23, 1972–1984
16 Reaves, B. J., Bright, N. A., Mullock, B. M. and Luzio, J. P. (1996) The effect of
wortmannin on the localisation of lysosomal type I integral membrane glycoproteins
suggests a role for phosphoinositide 3-kinase activity in regulating membrane trafﬁc late
in the endocytic pathway. J. Cell Sci. 109, 749–762
17 Reid, E., Connell, J., Edwards, T. L., Duley, S., Brown, S. E. and Sanderson, C. M. (2005)
The hereditary spastic paraplegia protein spastin interacts with the ESCRT-III
complex-associated endosomal protein CHMP1B. Hum. Mol. Genet. 14, 19–38
18 Sanderson, C. M., Connell, J. W., Edwards, T. L., Bright, N. A., Duley, S., Thompson, A.,
Luzio, J. P. and Reid, E. (2006) Spastin and atlastin, two proteins mutated in
autosomal-dominant hereditary spastic paraplegia, are binding partners. Hum. Mol.
Genet. 15, 307–318
19 Connell, J., Lindon, C., Luzio, J. and Reid, E. (2009) Spastin couples microtubule
severing to membrane trafﬁc in completion of cytokinesis and secretion. Trafﬁc 10,
42–56
20 Katzmann, D. J., Odorizzi, G. and Emr, S. D. (2002) Receptor downregulation and
multivesicular-body sorting. Nat. Rev. Mol. Cell. Biol. 3, 893–905
21 Cohen, A. W., Razani, B., Schubert, W., Williams, T. M., Wang, X. B., Iyengar, P.,
Brasaemle, D. L., Scherer, P. E. and Lisanti, M. P. (2004) Role of caveolin-1 in the
modulation of lipolysis and lipid droplet formation. Diabetes 53, 1261–1270
22 Ingham, R. J., Colwill, K., Howard, C., Dettwiler, S., Lim, C. S. H., Yu, J., Hersi, K.,
Raaijmakers, J., Gish, G., Mbamalu, G. et al. (2005) WW domains provide a platform for
the assembly of multiprotein networks. Mol. Cell. Biol. 25, 7092–7106
23 Robay, D., Patel, H., Simpson, M. A., Brown, N. A. and Crosby, A. H. (2006) Endogenous
spartin, mutated in hereditary spastic paraplegia, has a complex subcellular localization
suggesting diverse roles in neurons. Exp. Cell Res. 312, 2764–2777
24 Wang, X., Shaw, W. R., Tsang, H. T., Reid, E. and O’Kane, C. J. (2007) Drosophila
spichthyin inhibits BMP signaling and regulates synaptic growth and axonal
microtubules. Nat. Neurosci. 10, 177–185
24a Tsang, H. T., Edwards, T. L., Wang, X., Connell, J. W., Davies, R. J., Durrington, H. J.,
O’Kane, C. J., Luzio, J. P. and Reid, E. (2009) The hereditary spastic paraplegia proteins
NIPA1, spastin and spartin are inhibitors of mammalian BMP signaling. Hum. Mol.
Genet., doi:10.1093/hmg/ddp324
25 Simpson, M. A., Cross, H., Proukakis, C., Pryde, A., Hershberger, R., Chatonnet, A.,
Patton, M. A. and Crosby, A. H. (2003) Maspardin is mutated in mast syndrome, a
complicated form of hereditary spastic paraplegia associated with dementia. Am. J. Hum.
Genet. 73, 1147–1156
26 Hanein, S., Martin, E., Boukhris, A., Byrne, P., Goizet, C., Hamri, A., Benomar, A.,
Lossos, A., Denora, P., Fernandez, J. et al. (2008) Identiﬁcation of the SPG15 gene,
encoding spastizin, as a frequent cause of complicated autosomal-recessive spastic
paraplegia, including Kjellin syndrome. Am. J. Hum. Genet. 82, 992–1002
27 Welchman, R. L., Gordon, C. and Mayer, R. J. (2005) Ubiquitin and ubiquitin-like
proteins as multifunctional signals. Nat. Rev. Mol. Cell. Biol. 6, 599–609
28 Di Fiore, P. P., Polo, S. and Hofmann, K. (2003) When ubiquitin meets ubiquitin
receptors: a signalling connection. Nat. Rev. Mol. Cell. Biol. 4, 491–497
29 Hicke, L., Schubert, H. L. and Hill, C. P. (2005) Ubiquitin-binding domains. Nat. Rev.
Mol. Cell. Biol. 6, 610–621
30 Shearwin-Whyatt, L., Dalton, H. E., Foot, N. and Kumar, S. (2006) Regulation of
functional diversity within the Nedd4 family by accessory and adaptor proteins.
Bioessays 28, 617–628
Received 18 December 2008/4 June 2009; accepted 6 July 2009
Published as BJ Immediate Publication 6 July 2009, doi:10.1042/BJ20082398
c   The Authors Journal compilation c   2009 Biochemical Society © 2009 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.Biochem. J. (2009) 423, 31–39 (Printed in Great Britain) doi:10.1042/BJ20082398
SUPPLEMENTARY ONLINE DATA
Endogenous spartin (SPG20) is recruited to endosomes and lipid droplets
and interacts with the ubiquitin E3 ligases AIP4 and AIP5
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Figure S1 Minimal co-localization between spartin and endogenous markers
(A–G) HeLa cells were labelled with spartin (left-hand panels) and with endogenous protein markers of early endosomes (EEA1), lysosomes (Lamp1), clathrin (X22), the Golgi apparatus (GM130),
thetrans-Golginetwork(TGN46),theendoplasmicreticulum(KDEL)andmicrotubules(tubulin)(centrepanels).Right-handpanelsshowthemergedimages;thecolourofeachmarkerinthemerged
image is shown by the colour of its lettering in the non-merged panels. Scale bars=10μm.
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Figure S2 Spartin co-localizes with mitochondria
(A)Pre-ﬁxationtreatmentofHeLacellswithcytosolicextractionbufferremovescytosolicspartin
to reveal tubular/vesicular structures. (B) The signal in (A) was diminished by spartin siRNA
transfection. The image was taken with identical confocal microscope settings to those in (A).
(C) Spartin co-localizes with the mitochondrial marker MitoTracker in HeLa cells treated with
cytosol extraction buffer. The right-hand panel shows the merged images; the colour of each
marker in the merged image is shown by the colour of its lettering in the non-merged panels.
Scale bars=10μm.
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